

## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010

## FCGR2B RABBIT PAB

Cat.#: S217437

Product Name: Anti-FCGR2B Rabbit Polyclonal Antibody

Synonyms: CD32; FCG2; CD32B; FCGR2; IGFR2

UNIPROT ID: P31994 (Gene Accession - BC031992)

**Background:** The protein encoded by this gene is a low affinity receptor for the Fc region of immunoglobulin gamma complexes. The encoded protein is involved in the phagocytosis of immune complexes and in the regulation of antibody production by B-cells. Variations in this gene may increase susceptibility to systemic lupus erythematosus (SLE). Several transcript variants encoding different isoforms have been found for this gene.

Immunogen: Fusion protein of human FCGR2B

Applications: ELISA, WB, IHC

Recommended Dilutions: IHC: 50-200;WB: 500-2000;ELISA: 2000-5000

Host Species: Rabbit

Clonality: Rabbit Polyclonal

Isotype: Immunogen-specific rabbit IgG

Purification: Antigen affinity purification

Species Reactivity: Human

Constituents: PBS (without Mg2+ and Ca2+), pH 7.4, 150 mM NaCl, 0.05% Sodium Azide and 40% glycerol

Research Areas: Immunology, Stem Cells

Storage & Shipping: Store at -20°C. Avoid repeated freezing and thawing



## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010



Immunohistochemistry analysis of paraffin embedded Human liver cancer tissue using 217437(FCGR2B Antibody) at a dilution of 1/40(Cytoplasm).



The image on the left is immunohistochemistry of paraffin-embedded Human prostate cancer tissue using 217437(Anti-FCGR2B Antibody) at a dilution of 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human liver cancer tissue is first treated with the fusion protein and then with 217437(Anti-FCGR2B Antibody) at dilution 1/40.



In comparision with the IHC on the left, the same paraffin-embedded Human prostate cancer tissue is first treated with fusion protein and then with D222355(Anti-FCGR2B Antibody) at dilution 1/40.





## **Product Description**

Pioneering GTPase and Oncogene Product Development since 2010